Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

Wolfe, 1999, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med, 341, 1725, 10.1056/NEJM199912023412303

Laupacis, 1996, A study of the quality of life and cost-utility of renal transplantation, Kidney Int, 50, 235, 10.1038/ki.1996.307

Briggs, 2001, Causes of death after renal transplantation, Nephrol Dial Transplant, 16, 1545, 10.1093/ndt/16.8.1545

Pilmore, 2010, Reduction in cardiovascular death after kidney transplantation, Transplantation, 89, 851, 10.1097/TP.0b013e3181caeead

Engels, 2011, Spectrum of cancer risk among US solid organ transplant recipients, JAMA, 306, 1891, 10.1001/jama.2011.1592

Vajdic, 2006, Cancer incidence before and after kidney transplantation, JAMA, 296, 2823, 10.1001/jama.296.23.2823

Kasiske, 2000, Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation, J Am Soc Nephrol, 11, S1, 10.1681/ASN.V11suppl_1s1

Penn, 1996, Malignant melanoma in organ allograft recipients, Transplantation, 61, 274, 10.1097/00007890-199601270-00019

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339, b2535, 10.1136/bmj.b2535

De Toni, 2017, Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient, Gastroenterology, 152, 1631, 10.1053/j.gastro.2017.01.063

Ranganath, 2015, Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma, J Immunother, 38, 211

Friend, 2017, Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma, Pediatr Blood Cancer, 64, e26682, 10.1002/pbc.26682

Morales, 2015, Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation, J Immunother Cancer, 3, 22, 10.1186/s40425-015-0066-0

Schvartsman, 2017, Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma, Ann Intern Med, 167, 361, 10.7326/L17-0187

Biondani, 2018, Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient, Ann Oncol, 29, 286, 10.1093/annonc/mdx548

Kuo, 2018, Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review, Melanoma Res, 28, 61, 10.1097/CMR.0000000000000410

Owonikoko, 2017, Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report, Cancer Immunol Immunother, 66, 45, 10.1007/s00262-016-1918-2

Gastman, 2016, Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient, Ann Oncol, 27, 2304, 10.1093/annonc/mdw293

Covut, 2017, Nivolumab before and after allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, 52, 1054, 10.1038/bmt.2017.44

Angenendt, 2016, Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation, Bone Marrow Transplant, 51, 443, 10.1038/bmt.2015.266

Zehou, 2018, Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients, Am J Transplant, 18, 3065, 10.1111/ajt.15071

Tamain, 2016, Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma, Transplant Int, 29, 1247, 10.1111/tri.12834

Jose, 2016, Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature, Transplant Proc, 48, 3137, 10.1016/j.transproceed.2016.07.019

Gueguen, 2019, CMV disease and colitis in a kidney transplanted patient under pembrolizumab, Eur J Cancer, 109, 172, 10.1016/j.ejca.2018.12.027

Tio, 2018, Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection, Eur J Cancer, 104, 137, 10.1016/j.ejca.2018.09.017

Herz, 2016, Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient, Eur J Cancer, 67, 66, 10.1016/j.ejca.2016.07.026

Ong, 2016, Antitumor activity of nivolumab on hemodialysis after renal allograft rejection, J Immunother Cancer, 4, 64, 10.1186/s40425-016-0171-8

Akturk, 2018, PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity, J Clin Endocrinol Metab, 103, 3589, 10.1210/jc.2018-01430

Lipson, 2014, Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma, J Clin Oncol, 32, e69, 10.1200/JCO.2013.49.2314

Sadaat, 2018, Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy, J Oncol Pract, 14, 198, 10.1200/JOP.2017.027326

Winkler, 2017, Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature, J Immunother, 40, 341

Kwatra, 2017, Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report, J Med Case Rep, 11, 73, 10.1186/s13256-017-1229-z

Lesouhaitier, 2018, Checkpoint blockade after kidney transplantation, Eur J Cancer, 96, 111, 10.1016/j.ejca.2018.03.019

Spain, 2016, Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma, Ann Oncol, 27, 1135, 10.1093/annonc/mdw130

Singh, 2019, Preserved renal allograft function and successful treatment of metastatic Merkel cell cancer post nivolumab therapy, Transplantation, 103, E52, 10.1097/TP.0000000000002502

Goldman, 2018, PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - Case report, BMC Nephrol, 19, 210, 10.1186/s12882-018-1003-5

Boils, 2016, Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy, Am J Transplant, 16, 2496, 10.1111/ajt.13786

Alhamad, 2016, Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection, Am J Transplant, 16, 1332, 10.1111/ajt.13711

Lipson, 2016, Tumor regression and allograft rejection after administration of anti-PD-1, N Engl J Med, 374, 896, 10.1056/NEJMc1509268

Wu, 2017, Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration, Ann Oncol, 28, 2895, 10.1093/annonc/mdx409

Barnett, 2017, Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab: To the editor, N Engl J Med, 376, 191, 10.1056/NEJMc1614298

Deltombe, 2017, Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1 therapy in a kidney transplanted patient, Transplant Int, 30, 405

Coche, 2018, Immune checkpoint inhibitors in kidney transplant recipients, Transplant Int, 31, 13

Boyle, 2017, Donor-derived metastatic melanoma and checkpoint inhibition, Transplant Proc, 49, 1551, 10.1016/j.transproceed.2017.06.007

Kittai, 2017, Immune checkpoint inhibitors in organ transplant patients, J Immunother, 40, 277

Soellradl, 2018, The use of checkpoint-inhibitors in metastatic melanoma in a combined heart and kidney transplant recipient. A case report, Transplant Int, 31, 18

Miller, 2017, Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade, JAAD Case Rep, 3, 412, 10.1016/j.jdcr.2017.06.005

Mueller, 1989, Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy, Annu Rev Immunol, 7, 445, 10.1146/annurev.iy.07.040189.002305

Riella, 2012, Role of the PD-1 pathway in the immune response, Am J Transplant, 12, 2575, 10.1111/j.1600-6143.2012.04224.x

Peggs, 2005, Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily, Br J Haematol, 130, 809, 10.1111/j.1365-2141.2005.05627.x

Ding, 2005, PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis, Clin Immunol, 115, 184, 10.1016/j.clim.2005.01.005

Starke, 2010, Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses, Kidney Int, 78, 38, 10.1038/ki.2010.97

Kubica, 2012, Melanoma in immunosuppressed patients, Mayo Clin Proc, 87, 991, 10.1016/j.mayocp.2012.04.018

De Bruyn, 2019, Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?, Curr Opin Oncol, 31, 54, 10.1097/CCO.0000000000000505

Abdel-Wahab, 2019, Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature, J Immunother Cancer, 7, 106, 10.1186/s40425-019-0585-1

Venkatachalam K, Malone AF, Heady B, et al. Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients [e-pub ahead of print]. Transplantation. https://doi.org/10.1097/TP.0000000000002914. Accessed November 2, 2019.

Otley, 2006, Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey, Br J Dermatol, 154, 395, 10.1111/j.1365-2133.2005.07087.x

Hojo, 1999, Cyclosporine induces cancer progression by a cell-autonomous mechanism, Nature, 397, 530, 10.1038/17401

Maluccio, 2003, Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression, Transplantation, 76, 597, 10.1097/01.TP.0000081399.75231.3B

Opelz, 2004, Lymphomas after solid organ transplantation: a collaborative transplant study report, Am J Transplant, 4, 222, 10.1046/j.1600-6143.2003.00325.x

Dantal, 1998, Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens, Lancet, 351, 623, 10.1016/S0140-6736(97)08496-1

Yuan, 2008, Mutagenic and cytotoxic properties of 6-thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid, J Biol Chem, 283, 23665, 10.1074/jbc.M804047200

Luan, 2002, Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy, Transplantation, 73, 1565, 10.1097/00007890-200205270-00008

Luan, 2003, Rapamycin is an effective inhibitor of human renal cancer metastasis, Kidney Int, 63, 917, 10.1046/j.1523-1755.2003.00805.x

Kauffman, 2005, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies, Transplantation, 80, 883, 10.1097/01.TP.0000184006.43152.8D